245 related articles for article (PubMed ID: 7777769)
21. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
22. [The local therapy of distal colitis and ulcerative proctitis].
Scheppach W
Dtsch Med Wochenschr; 1993 May; 118(20):751-4. PubMed ID: 8099006
[No Abstract] [Full Text] [Related]
23. Medical management of patients with difficult-to-treat inflammatory bowel disease.
van Hogezand RA
Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006
[TBL] [Abstract][Full Text] [Related]
24. The mesalamine wars heat up-enter balsalazide.
Cohen RD
Gastroenterology; 2003 Feb; 124(2):574-5. PubMed ID: 12557164
[No Abstract] [Full Text] [Related]
25. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M
J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
[TBL] [Abstract][Full Text] [Related]
26. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
Hanauer SB
Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():37-40. PubMed ID: 16961743
[TBL] [Abstract][Full Text] [Related]
27. [Salazosulfapyridine and 5-aminosalicylic acid agents for the treatment of ulcerative colitis].
Aihara H; Hiwatashi N
Nihon Rinsho; 1999 Nov; 57(11):2476-80. PubMed ID: 10572415
[TBL] [Abstract][Full Text] [Related]
28. [The treatment of ulcerative colitis].
Turunen U; Järvinen HJ
Duodecim; 1993; 109(2):145-51. PubMed ID: 7912179
[No Abstract] [Full Text] [Related]
29. [Current focus on inflammatory intestinal diseases: Crohn's disease and ulcero-hemorrhagic rectocolitis].
Fontaine F; Brassinne A; Delforge M; Demoulin JC; Drèze C; Gillard V; Bastens B
Rev Med Liege; 1993 Nov; 48(11):593-618. PubMed ID: 7904768
[No Abstract] [Full Text] [Related]
30. Sulfasalazine and new analogues.
Friedman G
Am J Gastroenterol; 1986 Feb; 81(2):141-4. PubMed ID: 2868653
[No Abstract] [Full Text] [Related]
31. Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis.
Bardazzi G; d'Albasio G; Bonanomi AG; Trallori G; Messori A; Amorosi A; Bartoletti L; Morettini A; Pacini F
Ital J Gastroenterol; 1994 Sep; 26(7):334-7. PubMed ID: 7812025
[TBL] [Abstract][Full Text] [Related]
32. [Drug therapy of chronic inflammatory bowel disease--reliable standards and new developments].
Fischbach W
Leber Magen Darm; 1992 Mar; 22(2):49-55. PubMed ID: 1350043
[TBL] [Abstract][Full Text] [Related]
33. [Long-term therapy and timing of surgical intervention in ulcerative colitis and Crohn disease].
Goebell H; Eigler FW
Chirurg; 1992 Jan; 63(1):8-12. PubMed ID: 1347737
[No Abstract] [Full Text] [Related]
34. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
[TBL] [Abstract][Full Text] [Related]
35. Ulcerative colitis therapy: importance of delivery mechanisms.
Rochester J; Abreu MT
Rev Gastroenterol Disord; 2005; 5(4):215-22. PubMed ID: 16369217
[TBL] [Abstract][Full Text] [Related]
36. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
Baker DE; Kane S
Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
[TBL] [Abstract][Full Text] [Related]
37. [Ulcerative colitis. When is standard therapy enough?].
Stange EF
MMW Fortschr Med; 2000 Oct; 142(41):39-40. PubMed ID: 11085075
[No Abstract] [Full Text] [Related]
38. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study.
Ardizzone S; Petrillo M; Molteni P; Desideri S; Bianchi Porro G
J Clin Gastroenterol; 1995 Dec; 21(4):287-9. PubMed ID: 8583101
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacological bases of therapy with 5-ASA].
Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
[No Abstract] [Full Text] [Related]
40. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
Cohen HD; Das KM
J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
